Acute Leukemias VIII: Prognostic Factors and Treatment Strategies

Front Matter....Pages I-XXVII
Front Matter....Pages 1-1
Mechanisms of Chromosomal Translocation Breakpoints....Pages 3-10
Hematologic Malignancies Following Organ Transplantation....Pages 11-14
Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders....Pages 15-19
Molecular Characterization of the Translocation (10;11)(p13;q14): MLL and CALM are Fused to AF10 in Morphologically Different Subsets of Acute Leukemia....Pages 20-26
MLL-Duplications are Rare and Associated with Poor Prognosis in Acute Myeloid Leukemia....Pages 27-33
Real-Time RT-PCR for the Detection and Quantification of AML1/MTG8 Fusion Transcripts in Patients with t(8;21) Positive AML....Pages 34-39
Combined Cytogenetic, FISH and RT-PCR Technique in Detection of t(15;17) and Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia....Pages 40-43
RT-PCR in Diagnostics and Monitoring of Acute Myeloid....Pages 44-48
Chromosome Aberrations in Primary and Secondary Acute Myeloblastic Leukemia (AML)....Pages 49-53
Are there Two Main Categories of de Novo Acute Myeloid Leukemias with a Normal Karyotype?....Pages 54-60
Asynchronous Expression of AC133 on CD34-Negative Leukemic Blast Cells in Childhood B-Cell Precursor ALL....Pages 61-63
Expression of AC133 in Childhood Acute Leukemia....Pages 64-71
CD10 Expression in T-Lineage Adult Acute Lymphoblastic Leukemia....Pages 72-77
Acute Lymphoblastic Leukemia in Childhood with an Unusual Immunophenotype (CD7 +/CD56 +/CD33 +)....Pages 78-84
Expression of IGFBP-rP2 / CTGF is Specific for Malignant Lymphoblasts of Children with Acute Lymphoblastic Leucemia (ALL)....Pages 85-88
NM23-H1 Protein Expression as a New Prognostic Factor in Acute Lymphoblastic Leukemia....Pages 89-95
Monitoring of Wilms’ Tumor Gene Transcription in Leukemia Patients....Pages 96-99
Effect of Mutationally Activated Ras on the Ras to MAP Kinase Signaling Pathway and Growth Inhibition of Myeloid Leukemia Cells by Inhibitors of the MAP Kinase Cascade....Pages 100-108
C-Jun is a JNK-Independent Coactivator of the PU.1 Transcription Factor....Pages 109-111
CD7+ and CD56+ Acute Myelogenous Leukemia is a Distinct Biologic and Clinical Disease Entity....Pages 112-119
Front Matter....Pages 1-1
The Role of Apoptosis in the Course of Acute Leukemia in Children....Pages 120-123
Evaluation of Spontaneous and Therapeutically Induced Apoptosis in Childhood Leukemias....Pages 124-127
Involvement of BCL-2 and Bax in the IL-7-lnduced Inhibition of Spontaneous Apoptosis in Childhood T-ALL....Pages 128-135
Analysis of the Apoptotic Signal Transduction Cascade and New Differentially Expressed Genes in Drug Resistant and Sensitive Hematopoetic Cell Lines....Pages 136-145
Transforming Activity of Flt3 in 32D Cells....Pages 146-151
Evidence of Angiogenesis in Acute Myeloid Leukemia....Pages 152-159
Significance of AC133 and CD34 Expression on Acute Myeloid Leukemia Cells....Pages 160-165
Heterogeneity in the Stem Cell Compartment of Newly Diagnosed Acute Myeloid Leukemia Analyzed by 4-Colour Immunofluorescence....Pages 166-168
Validation of the IPSS and Other Scoring Systems in Patients with Primary MDS....Pages 169-171
Although Patients with AML and Complex Aberrant Karyotype Can be Subdivided Into Different Subtypes by Cytogenetics, Prognosis is Equally Poor....Pages 172-175
Front Matter....Pages 177-177
Pharmacokinetics of Idarubicin: Intracellular Events and Extracellular Concentrations....Pages 179-183
Oral Idarubicin in Maintenance Therapy of Acute Myeloid Leukemia....Pages 184-190
Phase I Study of Liposomal Daunorubicin (DaunoXome) in Relapsed and Refractory Acute Myeloid Leukemia....Pages 191-195
Multi Centre Study of a Combination of Fludarabine Phosphate, Cytosine Arabinoside and Granulocyte Colony Stimulating Factor (FLAG) in Relapsed and Refractory Acute Myeloid Leukaemia and in De Novo RAEB-t....Pages 196-200
Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG....Pages 201-209
Colony Stimulating Factors in Myelodysplastic Syndromes....Pages 210-217
Modulation of Ara-CToxification by Fludarabine and Hydroxyurea in Leukemic Blasts....Pages 218-222
Drug Monitoring of Doxorubicin in Children....Pages 223-226
Pharmacokinetics of Daunorubicin Entrapped in Liposomes or Erythrocytes—Phase II Study in Refractory Acute Leukemias....Pages 227-230
Drug Monitoring During Maintenance Therapy In Children with ALL....Pages 231-235
Front Matter....Pages 177-177
Modulation of Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia; Preliminary Results....Pages 236-243
In-Vitro Cellular Drug Resistance in Acute Non-Lymhoblastic Leukemia: Comparisons Between Adults and Children....Pages 244-250
Prognostic Relevance of In-Vitro Drug Sensitivity Testing in Adult AML....Pages 251-256
Antileukemic Effects of Buthionine Sulfoximine (BSO) (NSC 326231) in Vivo: A Pilot Study in Acute Myeloblastic Leukemia....Pages 257-264
Dendritic Cells Generated out of Blasts from Patients with Acute Leukemia....Pages 265-272
Generation of Leukemia-Derived Dendritic Cells from Patients with AML....Pages 273-281
Dendritic Cells from AML Patients in Complete Remission are Capable to Present Antigen to Autologous T Lymphocytes....Pages 282-286
Antibody Response to Neuraminidase of the Influenza Virus in Children with Acute Lymphoblastic Leukaemia Vaccinated against Influenza after Chemotherapy....Pages 287-290
Expansion and Fibronectin-Enhanced Retroviral Transduction of Primary Human T Lymphocytes for Adoptive Immunotherapy....Pages 291-306
Front Matter....Pages 307-307
Early Empiric Antifungal Treatment of Infections in Neutropenic Patients with Hematological Malignancies Comparing Fluconazole with Amphotericin B and 5-Flucytosine....Pages 309-314
The Role of Newer Quinolones in the Management of Infections in Patients with Hematologic Malignancies....Pages 315-320
Fungal Infections in Paediatric Haematology....Pages 321-323
Empirical Antimicrobial Therapy of FUO and Proved Infections in Neutropenic Patients....Pages 324-329
Multivariate Analysis of Prognostic Factors in Patients with Refractory and Relapsed Acute Myeloid Leukemia Undergoing Sequential High-Dose Cytosine Arabinoside and Mitoxantrone (S-HAM) Salvage Therapy: Significance of Cytogenetic Abnormalities....Pages 330-338
Incidence of Central Venous Catheter (CVC)-lnfections in Patients with Acute Leukemia....Pages 339-343
Do we Need a Triple Antibiotic Therapy?....Pages 344-345
Study of G-CSF Influences on CD10 and CD64 Distribution on Neutrophils in Leukemic Patients....Pages 346-352
RHuGM-CSF (Molgramostim) in the Treatment of Children and Adolescents with Acute Myeloid Leukemia....Pages 353-355
Front Matter....Pages 357-357
CCG Experience with the Augmented BFM Regimen....Pages 359-363
Pharmacodynamics in Childhood Acute Lymphoblastic Leukemia....Pages 364-369
Front Matter....Pages 357-357
The Late Effects of Prophylactic CNS Treatment*....Pages 370-380
The Use of PEG-Asparaginase in Leukemic Children with Prior Hypersensitivity to Native L-Asparaginase....Pages 381-383
The Importance of MRI in Detection of Primary CNS Involvement in Leukaemic Children....Pages 384-386
Front Matter....Pages 387-387
Treatment of Adult Acute Lymphoblastic Leukemia Long Term Results of a Prospective Study: LALA 87....Pages 389-392
Results of Recent Clinical Trials in Acute Lymphoblastic Leukemia by the Cancer and Leukemia Group B....Pages 393-401
Early Application of Anthracyclines in Adult Acute Lymphoblastic Leukemia (ALL)....Pages 402-413
Allogeneic Bone Marrow Transplantation for BCR-ABL Positive Acute Lymphoblastic Leukemia....Pages 414-418
Preliminary Results of a Risk-Oriented Program for B-Lineage Adult Acute Lymphoblastic Leukemia (ALL): The Collaborative Italian Study 08/96....Pages 419-425
Prognostic Factors in Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia....Pages 426-431
High-Dose Cytarabine Combined to Mitoxantrone in the Treatment of Refractory and Relapsed Acute Lymphoblastic Leukemia....Pages 432-437
Split-Course High-Dose ARA-C Plus Idarubicin and Multidrug Blockade by short Cyclosporin-A Infusion for Refractory Acute Myeloid Leukemia....Pages 438-445
Front Matter....Pages 447-447
Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B....Pages 449-456
The Impact of Treatment on the Outcome of Cytogenetic Subgroups in Acute Myeloid Leukemia -Results of the German AML Cooperative Group....Pages 457-460
High Dose Cytosine Arabinoside Combined with an Anthracycline as Remission Induction in Acute Myeloid Leukemia....Pages 461-463
Comparison of the Efficacy of TAD-TAD and “7+3” Regimens in Adult AML, the Role of Dose Intensity and Mdr-1 Gene Expression....Pages 464-469
Stratification of Postremission Therapy in Patients with Acute Myeloid Leukemia < 60 Years According to the Karyotype: Results of the German Multicenter Treatment Trials AML HD93 and AML HD98-A....Pages 470-476
Phase I Trial of Docetaxel (Taxotere) for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)....Pages 477-481
Including Quality of Life as an Important End Point in Evaluating Intensive and Prolonged Treatment for Acute Myeloid Leukemia (AML)....Pages 482-487
The 10.000/μl Morning Trigger for Prophylactic Platelet Transfusion is Safe: Prospective Experience in 411 AML Patients....Pages 488-490
Front Matter....Pages 491-491
Prognostic Factors and Patterns of Failure in Childhood Acute Myeloid Leukemia: Experience on Pediatric Oncology Group Study # 8821....Pages 493-498
Front Matter....Pages 491-491
Early Response to Therapy is the Strongest Prognostic Factor in Childhood AML....Pages 499-507
Long-Term Outcome and Prognostic Factors in Children’s Cancer Group Study 2891 for Children and Adolescents with Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome....Pages 508-518
Risk-Adapted Therapy and Randomization in Children with AML: Preliminary Results of Study AML-BFM 93....Pages 519-524
Acute Myeloid Leukemia (AML) in Children: Results of the French Trials....Pages 525-530
AML in Children: The Medical Research Council Data....Pages 531-540
Preliminary Results of a Multicentre Therapy Study for the Treatment of Children and Adolescents with AML in the Ukraine....Pages 541-543
IDA-FLAG—An Effective Reinduction Therapy for Poor Prognosis AML of Childhood—Report of a Multicenter Phase II Trial....Pages 544-554
Front Matter....Pages 555-555
APL Biology....Pages 557-561
Molecular Diagnosis and Monitoring of Acute Promyelocytic Leukemia: Updated Results of the Italian Gimema Group....Pages 562-564
All-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia....Pages 565-569
Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide....Pages 570-577
Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia....Pages 578-587
Acute Promyelocytic Leukemia and Pregnancy....Pages 588-591
Severe Laryngeal Edema in Acute Promyelocytic Leukemia under All-Trans Retinoic Acid....Pages 592-595
Extramedullar Acute Promyelocytic Leukemia....Pages 596-603
Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B....Pages 604-608
Front Matter....Pages 609-609
Treatment of Older Patients with Acute Myeloid Leukemia (AML)....Pages 611-620
AML in the Elderly....Pages 621-627
The EORTC-HOVON Approach to the Older Patient with AML: The Use of GM CSF....Pages 628-630
Therapy of Older Adults with AML: CALGB Studies....Pages 631-638
Front Matter....Pages 609-609
Treatment of Older Adults with Acute Myelogenous Leukemia: Studies of the Eastern Cooperative Oncology Group (ECOG)....Pages 639-643
A Landmark Analysis of Survival by Response Category in Elderly Patients with Acute Myeloblastic Leukemia....Pages 644-646
Front Matter....Pages 647-647
Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes....Pages 649-654
Secondary Leukemia or Myelodysplasia Treated by Bone Marrow Transplantation....Pages 655-659
Comparison of Intensive Chemotherapy and Autologous Transplantation as Post Remission Therapy in Adult Acute Myeloid Leukemia. Update of the GOELAM 1 Trial....Pages 660-664
Adoptive Immunotherapy of Acute Leukemia and Acute Phase Chronic Myeloid Leukemia after Allogeneic Bone Marrow Transplantation....Pages 665-673
Shifting Towards Better Immunotherapy Rather Than More Intensive Chemoradiotherapy Using a Non-Myeloablative Approach in Patients with Leukemia....Pages 674-677
Long-Term Results of Autologous Bone Marrow Transplantation as Late Intensification in AML....Pages 678-682
Results of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk MDS....Pages 683-684
Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients....Pages 685-694
Analysis of Chimerism in the Early Posttransplantation Period in Cellular Subsets of Patients Undergoing Myeloablative and Non-Myeloablative (Metakine) Allogeneic Blood Stem Cell Transplantation (BSCT)....Pages 695-697
Somnolence Syndrome after Total Body Irradiation in Children with Bone Marrow Transplantation....Pages 698-705
Ten Years of Autologous Stem Cell Transplantation in Acute Leukemia: Single Center Experience in 46 Patients....Pages 706-710
Transplant Characteristics: Minimal Residual Disease and Impaired Megakaryocytic Colony Growth as Sensitive Parameters for Predicting Relapse in Acute Myeloid Leukemia....Pages 711-719
Back Matter....Pages 721-724